A new alpha-radioimmunotherapy (α-RIT)  tool was reported in the Journal of Nuclear Medicine this month. Researchers in Limoges University, France developed α-RIT with ²¹²Pb-daratumumab (anti-hCD38) for the treatment of multiple myeloma, a plasma cell cancer which is the second most frequent hematologic malignancy. Despite new treatments and protocols, including high-dose chemotherapy associated with autologous stem cell transplantation, the prognosis of multiple myeloma patients is still poor.

Marked tumor growth inhibition compared with controls was observed, with a median survival of 55 d for 277.5 kBq of ²¹²Pb-daratumumab instead of 11 d for phosphate-buffered saline. These results showed ²¹²Pb-daratumumab to have efficacy in xenografted mice, with significant tumor regression and increased survival. This study highlights the potency of α-RIT in multiple myeloma treatment.

To read more please visit:

http://jnm.snmjournals.org/content/61/7/1058

Source: JNM